Literature DB >> 1370217

Dextran administration avoids hemodynamic changes following paracentesis in cirrhotic patients. A safe and inexpensive option.

R Terg1, J Berreta, R Abecasis, G Romero, L Boerr.   

Abstract

Paracentesis associated with albumin administration has been shown to be a safe and useful procedure in the treatment of patients with cirrhosis and ascites. Given the high cost of albumin, 20 patients with cirrhosis and ascites were treated in an open study, with daily paracentesis using dextran 70, an inexpensive volume expander, instead of albumin. In the first 10 patients, hemodynamic evaluation was performed in basal conditions, after each paracentesis (5 liter), and after dextran infusion. Twelve hours after each paracentesis without expansion, a significant drop in pulmonary capillary wedge pressure from 9.5 +/- 1.0 to 7.1 +/- 1.7 (P less than 0.01) and a reduction in cardiac output from 6.6 +/- 1.0 to 5.0 +/- 1.9 (NS) were observed. Moreover, the hematocrit rose significantly from 36.8 +/- 5.6 to 39.2 +/- 4.8 (P less than 0.01). These parameters returned to baseline values after the administration of 84 +/- 14 ml of dextran 70 for each 1000 ml of ascites removed. The other 10 patients received dextran 70 simultaneously with the paracentesis without hemodynamic control. No significant changes in renal and hepatic functions were observed at the end of the study. The mean volume of ascites removed was 12.3 +/- 4.6 liter. Two patients developed hyponatremia that required no treatment. No patient developed renal failure. One patient died because of gastrointestinal bleeding.(ABSTRACT TRUNCATED AT 250 WORDS)

Entities:  

Mesh:

Substances:

Year:  1992        PMID: 1370217     DOI: 10.1007/bf01308346

Source DB:  PubMed          Journal:  Dig Dis Sci        ISSN: 0163-2116            Impact factor:   3.199


  18 in total

1.  Gastro-intestinal excretion of dextran-C14.

Authors:  B ABERG; W L BLOOM; E HANSSON
Journal:  Acta Physiol Scand       Date:  1961-06

2.  The source of albumin in the thoracic duct lymph in patients with portal hypertension and ascites.

Authors:  J L Boyer; W C Maddrey; A K Basu; F L Iber
Journal:  Am J Med Sci       Date:  1969-01       Impact factor: 2.378

Review 3.  Medical therapy of acute myocardial infarction by application of hemodynamic subsets (first of two parts).

Authors:  J S Forrester; G Diamond; K Chatterjee; H J Swan
Journal:  N Engl J Med       Date:  1976-12-09       Impact factor: 91.245

4.  Hemodynamics in the cirrhotic patient during paracentesis.

Authors:  C M Knauer; H M Lowe
Journal:  N Engl J Med       Date:  1967-03-02       Impact factor: 91.245

5.  Dextran-70 versus albumin as plasma expanders in cirrhotic patients with tense ascites treated with total paracentesis. Results of a randomized study.

Authors:  R Planas; P Ginès; V Arroyo; J Llach; J Panés; V Vargas; J M Salmerón; A Ginès; C Toledo; A Rimola
Journal:  Gastroenterology       Date:  1990-12       Impact factor: 22.682

6.  SERUM ALBUMIN TURNOVER IN NORMAL SUBJECTS AND PATIENTS WITH CIRRHOSIS MEASURED BY 131I-LABELLED HUMAN ALBUMIN.

Authors:  P WILKINSON; C L MENDENHALL
Journal:  Clin Sci       Date:  1963-10       Impact factor: 6.124

7.  Effect of dextran on factor VIII (antihemophilic factor) and platelet function.

Authors:  M Aberg; U Hedner; S E Bergentz
Journal:  Ann Surg       Date:  1979-02       Impact factor: 12.969

8.  Comparison of paracentesis and diuretics in the treatment of cirrhotics with tense ascites. Results of a randomized study.

Authors:  P Ginés; V Arroyo; E Quintero; R Planas; F Bory; J Cabrera; A Rimola; J Viver; J Camps; W Jiménez
Journal:  Gastroenterology       Date:  1987-08       Impact factor: 22.682

9.  Effects of therapeutic paracentesis on systemic and hepatic hemodynamics and on renal and hormonal function.

Authors:  D M Simon; J R McCain; H L Bonkovsky; J O Wells; D K Hartle; J T Galambos
Journal:  Hepatology       Date:  1987 May-Jun       Impact factor: 17.425

Review 10.  Clinical pharmacokinetic considerations in the use of plasma expanders.

Authors:  U Klotz; H Kroemer
Journal:  Clin Pharmacokinet       Date:  1987-02       Impact factor: 6.447

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.